Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

Inclusion Criteria: * Male and female patients with non-infectious intermediate or posterior uveitis or panuveitis in at least one eye, age 18 to 70 years of age inclusive, who are otherwise in good health * Macular edema with average central retinal thickness ≥ 250 µm * A vitreous haze score ≥ 1, but ≤ 3 (based on the National Eye Institute grading system) * Best Corrected Visual Acuity no worse than 20/400 and no better than 20/40 * Daily prednisone dose \< 1 mg/kg Exclusion Criteria: * Patients with choroidal neovascularization. * Patients with the following forms of uveitis: 1. Serpiginous choroidopathy 2. Acute multifocal placoid pigment epitheliopathy 3. White dot retino-choroidopathies (e.g., multiple evanescent white dot syndrome (MEWDS) or multifocal choroiditis) * Macular edema associated with other ocular disease (e.g., diabetic retinopathy) * Patients who had a prior vitrectomy * Any eye condition that may affect the evaluation of visual acuity and retinal thickness * Concurrent use of certain immunosuppressive agents (specific washout periods for different agents are defined in the protocol) * Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g. deferoxamine, chloroquine, and ethambutol) currently or in the past 6 months * Other protocol-defined inclusion/exclusion criteria may apply